Showing results (1-10 of 141) with videos related to
Sort By:
Pageof 15
Expert Opinion on Pharmacotherapy|May 9, 2017
Hormone-receptor positive breast cancer: highlights from the 39TH San Antonio Breast Cancer SymposiumGiorgia Zucchini, Filippo MontemurroEndocrine-Related Cancer|September 4, 2009
Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapyFilippo Montemurro, Massimo AgliettaClinical Breast Cancer|May 19, 2005
Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancerFilippo Montemurro, Massimo AgliettaThe Journal of Pathology|October 10, 2013
Biomarkers of drugs targeting HER-family signalling in cancerFilippo Montemurro, Maurizio ScaltritiExpert Opinion on Pharmacotherapy|April 23, 2004
Selected highlights from the 26th San Antonio Breast Cancer Symposium. December 3-6, 2003, San Antonio, TX, USAFilippo Montemurro, Massimo AgliettaExpert Opinion on Biological Therapy|January 26, 2007
Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activityFilippo Montemurro, Giorgio Valabrega, Massimo AgliettaExpert Opinion on Pharmacotherapy|December 19, 2003
Trastuzumab-based combination therapy for breast cancerFilippo Montemurro, Giorgio Valabrega, Massimo AgliettaExpert Opinion on Pharmacotherapy|April 3, 2020
Neoadjuvant or adjuvant chemotherapy in early breast cancer?Filippo Montemurro, Imperia Nuzzolese, Riccardo PonzoneExpert Opinion on Pharmacotherapy|April 5, 2014
2013 San Antonio Breast Cancer SymposiumValentina Rossi, Rossella Martinello, Caterina Aversa, et al.Expert Opinion on Pharmacotherapy|June 17, 2005
Controversies in breast cancer: adjuvant and neoadjuvant therapyFilippo Montemurro, Stefania Redana, Giorgio Valabrega, et al.Pageof 15